Patents by Inventor Qiaohua Kang

Qiaohua Kang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190271041
    Abstract: The present disclosure provides genetically engineered cell lines comprising chromosomally integrated synthetic sequences having predetermined epigenetic modifications, wherein a predetermined epigenetic modification is correlated with a known diagnosis, prognosis or level of sensitivity to a disease treatment. Also provided are kits comprising said epigenetically modified synthetic nucleic acids or cells comprising said epigenetically modified synthetic nucleic acids that can be used as reference standards for predicting responsiveness to therapeutic treatments, diagnosing diseases, or predicting disease prognosis.
    Type: Application
    Filed: January 14, 2019
    Publication date: September 5, 2019
    Inventors: Gregory D. Davis, Qiaohua Kang
  • Patent number: 10227610
    Abstract: Methods and compositions for increasing nuclease-mediated genomic modification using DNA repair inhibitors are provided.
    Type: Grant
    Filed: February 24, 2014
    Date of Patent: March 12, 2019
    Assignees: Sangamo Therapeutics, Inc., Sigma Aldrich Co LLC
    Inventors: Fuqiang Chen, Qiaohua Kang, Thomas Wechsler
  • Publication number: 20170073705
    Abstract: The present invention provides RNA-guided endonucleases, which are engineered for expression in eukaryotic cells or embryos, and methods of using the RNA-guided endonuclease for targeted genome modification in in eukaryotic cells or embryos. Also provided are fusion proteins, wherein each fusion protein comprises a CRISPR/Cas-like protein or fragment thereof and an effector domain. The effector domain can be a cleavage domain, an epigenetic modification domain, a transcriptional activation domain, or a transcriptional repressor domain. Also provided are methods for using the fusion proteins to modify a chromosomal sequence or regulate expression of a chromosomal sequence.
    Type: Application
    Filed: November 3, 2016
    Publication date: March 16, 2017
    Inventors: Fuqiang CHEN, Gregory D. DAVIS, Qiaohua KANG, Scott W. KNIGHT
  • Publication number: 20170051354
    Abstract: The present disclosure provides genetically engineered cell lines comprising chromosomally integrated synthetic sequences having predetermined epigenetic modifications, wherein a predetermined epigenetic modification is correlated with a known diagnosis, prognosis or level of sensitivity to a disease treatment. Also provided are kits comprising said epigenetically modified synthetic nucleic acids or cells comprising said epigenetically modified synthetic nucleic acids that can be used as reference standards for predicting responsiveness to therapeutic treatments, diagnosing diseases, or predicting disease prognosis.
    Type: Application
    Filed: April 24, 2015
    Publication date: February 23, 2017
    Applicant: SIGMA-ALDRICH CO. LLC
    Inventors: Gregory D. DAVIS, Qiaohua KANG
  • Publication number: 20160298133
    Abstract: The present invention provides RNA-guided endonucleases, which are engineered for expression in eukaryotic cells or embryos, and methods of using the RNA-guided endonuclease for targeted genome modification in in eukaryotic cells or embryos. Also provided are fusion proteins, wherein each fusion protein comprises a CRISPR/Cas-like protein or fragment thereof and an effector domain. The effector domain can be a cleavage domain, an epigenetic modification domain, a transcriptional activation domain, or a transcriptional repressor domain. Also provided are methods for using the fusion proteins to modify a chromosomal sequence or regulate expression of a chromosomal sequence.
    Type: Application
    Filed: June 21, 2016
    Publication date: October 13, 2016
    Inventors: Fuqiang CHEN, Gregory D. DAVIS, Qiaohua KANG, Scott W. KNIGHT
  • Publication number: 20160298132
    Abstract: The present invention provides RNA-guided endonucleases, which are engineered for expression in eukaryotic cells or embryos, and methods of using the RNA-guided endonuclease for targeted genome modification in eukaryotic cells or embryos. Also provided are fusion proteins, wherein each fusion protein comprises a CRISPR/Cas-like protein or fragment thereof and an effector domain. The effector domain can be a cleavage domain, an epigenetic modification domain, a transcriptional activation domain, or a transcriptional repressor domain. Also provided are methods for using the fusion proteins to modify a chromosomal sequence or regulate expression of a chromosomal sequence.
    Type: Application
    Filed: June 21, 2016
    Publication date: October 13, 2016
    Inventors: Fuqiang CHEN, Gregory D. DAVIS, Qiaohua KANG, Scott W. KNIGHT
  • Publication number: 20160298134
    Abstract: The present invention provides RNA-guided endonucleases, which are engineered for expression in eukaryotic cells or embryos, and methods of using the RNA-guided endonuclease for targeted genome modification in in eukaryotic cells or embryos. Also provided are fusion proteins, wherein each fusion protein comprises a CRISPR/Cas-like protein or fragment thereof and an effector domain. The effector domain can be a cleavage domain, an epigenetic modification domain, a transcriptional activation domain, or a transcriptional repressor domain. Also provided are methods for using the fusion proteins to modify a chromosomal sequence or regulate expression of a chromosomal sequence.
    Type: Application
    Filed: June 21, 2016
    Publication date: October 13, 2016
    Inventors: Fuqiang CHEN, Gregory D. DAVIS, Qiaohua KANG, Scott W. KNIGHT
  • Publication number: 20160298137
    Abstract: The present invention provides RNA-guided endonucleases, which are engineered for expression in eukaryotic cells or embryos, and methods of using the RNA-guided endonuclease for targeted genome modification in in eukaryotic cells or embryos. Also provided are fusion proteins, wherein each fusion protein comprises a CRISPR/Cas-like protein or fragment thereof and an effector domain. The effector domain can be a cleavage domain, an epigenetic modification domain, a transcriptional activation domain, or a transcriptional repressor domain. Also provided are methods for using the fusion proteins to modify a chromosomal sequence or regulate expression of a chromosomal sequence.
    Type: Application
    Filed: June 21, 2016
    Publication date: October 13, 2016
    Inventors: Fuqiang CHEN, Gregory D. DAVIS, Qiaohua KANG, Scott W. KNIGHT
  • Publication number: 20160298135
    Abstract: The present invention provides RNA-guided endonucleases, which are engineered for expression in eukaryotic cells or embryos, and methods of using the RNA-guided endonuclease for targeted genome modification in in eukaryotic cells or embryos. Also provided are fusion proteins, wherein each fusion protein comprises a CRISPR/Cas-like protein or fragment thereof and an effector domain. The effector domain can be a cleavage domain, an epigenetic modification domain, a transcriptional activation domain, or a transcriptional repressor domain. Also provided are methods for using the fusion proteins to modify a chromosomal sequence or regulate expression of a chromosomal sequence.
    Type: Application
    Filed: June 21, 2016
    Publication date: October 13, 2016
    Inventors: Fuqiang CHEN, Gregory D. DAVIS, Qiaohua KANG, Scott W. KNIGHT
  • Publication number: 20160298125
    Abstract: The present invention provides RNA-guided endonucleases, which are engineered for expression in eukaryotic cells or embryos, and methods of using the RNA-guided endonuclease for targeted genome modification in in eukaryotic cells or embryos. Also provided are fusion proteins, wherein each fusion protein comprises a CRISPR/Cas-like protein or fragment thereof and an effector domain. The effector domain can be a cleavage domain, an epigenetic modification domain, a transcriptional activation domain, or a transcriptional repressor domain. Also provided are methods for using the fusion proteins to modify a chromosomal sequence or regulate expression of a chromosomal sequence.
    Type: Application
    Filed: June 21, 2016
    Publication date: October 13, 2016
    Inventors: Fuqiang CHEN, Gregory D. DAVIS, Qiaohua KANG, Scott W. KNIGHT
  • Publication number: 20160298138
    Abstract: The present invention provides RNA-guided endonucleases, which are engineered for expression in eukaryotic cells or embryos, and methods of using the RNA-guided endonuclease for targeted genome modification in in eukaryotic cells or embryos. Also provided are fusion proteins, wherein each fusion protein comprises a CRISPR/Cas-like protein or fragment thereof and an effector domain. The effector domain can be a cleavage domain, an epigenetic modification domain, a transcriptional activation domain, or a transcriptional repressor domain. Also provided are methods for using the fusion proteins to modify a chromosomal sequence or regulate expression of a chromosomal sequence.
    Type: Application
    Filed: June 21, 2016
    Publication date: October 13, 2016
    Inventors: Fuqiang CHEN, Gregory D. DAVIS, Qiaohua KANG, Scott W. KNIGHT
  • Publication number: 20160298136
    Abstract: The present invention provides RNA-guided endonucleases, which are engineered for expression in eukaryotic cells or embryos, and methods of using the RNA-guided endonuclease for targeted genome modification in in eukaryotic cells or embryos. Also provided are fusion proteins, wherein each fusion protein comprises a CRISPR/Cas-like protein or fragment thereof and an effector domain. The effector domain can be a cleavage domain, an epigenetic modification domain, a transcriptional activation domain, or a transcriptional repressor domain. Also provided are methods for using the fusion proteins to modify a chromosomal sequence or regulate expression of a chromosomal sequence.
    Type: Application
    Filed: June 21, 2016
    Publication date: October 13, 2016
    Inventors: Fuqiang CHEN, Gregory D. DAVIS, Qiaohua KANG, Scott W. KNIGHT
  • Publication number: 20160017366
    Abstract: The present invention provides RNA-guided endonucleases, which are engineered for expression in eukaryotic cells or embryos, and methods of using the RNA-guided endonuclease for targeted genome modification in eukaryotic cells or embryos. Also provided are fusion proteins, wherein each fusion protein comprises a CRISPR/Cas-like protein or fragment thereof and an effector domain. The effector domain can be a cleavage domain, an epigenetic modification domain, a transcriptional activation domain, or a transcriptional repressor domain. Also provided are methods for using the fusion proteins to modify a chromosomal sequence or regulate expression of a chromosomal sequence.
    Type: Application
    Filed: December 5, 2013
    Publication date: January 21, 2016
    Applicant: SIGMA-ALDRICH CO. LLC
    Inventors: Fuqiang CHEN, Gregory D. DAVIS, Qiaohua KANG, Scott W. KNIGHT
  • Publication number: 20140242702
    Abstract: Methods and compositions for increasing nuclease-mediated genomic modification using DNA repair inhibitors are provided.
    Type: Application
    Filed: February 24, 2014
    Publication date: August 28, 2014
    Inventors: Fuqiang Chen, Qiaohua Kang, Thomas Wechsler